[Research and development progress of pneumococcal conjugate vaccines based on the serotype distribution

C L Fan1, H Zheng2, M Zeng3

  • 1Department of Vacciology, School of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.

Insights

Streptococcus pneumoniae (Spn) causes significant global disease. This review examines Spn serotype distribution, diseases, and antimicrobial resistance in China, informing pneumococcal conjugate vaccine (PCV) strategies.

Area of Science:

  • Microbiology
  • Immunology
  • Public Health

Background:

  • Streptococcus pneumoniae (Spn) is a leading cause of global morbidity and mortality, particularly in young children and the elderly.
  • Over 100 Spn serotypes exist, with capsular polysaccharides mediating immune evasion and disease pathogenicity.
  • Pneumococcal conjugate vaccines (PCVs) are crucial for preventing Spn-related diseases, but dynamic serotype distribution changes necessitate ongoing surveillance.

Purpose of the Study:

  • To systematically review Spn serotype distribution and associated diseases in China.
  • To analyze the current status of antimicrobial resistance in Spn.
  • To evaluate PCV immune mechanisms, immunogenicity, and protective effects, guiding future vaccine development and immunization strategies.

Main Methods:

  • Systematic literature review of Spn serotype distribution, diseases, and antimicrobial resistance in China.
  • Analysis of immune protective mechanisms of PCVs against various serotypes.
  • Comparative assessment of immunogenicity and efficacy of PCVs with different valences.

Main Results:

  • Dynamic changes in Spn serotype distribution observed in China following PCV implementation.
  • Accumulation of real-world evidence on PCV use and effectiveness.
  • Characterization of antimicrobial resistance patterns in circulating Spn strains.

Conclusions:

  • Evidence supports the need for updated PCV serotype coverage and optimized immunization strategies in China.
  • Further research into higher-valent and universal pneumococcal vaccines is warranted.
  • Understanding serotype dynamics is critical for effective pneumococcal disease control.